Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Study of STX-478 in Advanced Solid Tumors
jRCT2031250315Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2025
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of tersolisib in breast cancer, Nonhematologic neoplasms, gynecological cancer and 2 more (11 arms), sponsored by Eli Lilly and Company. Primary endpoint: Dose Limiting Toxicities within first 28 days. Started Dec 2025; status: recruiting.
02
Drugs
tersolisib
03
Conditions
breast cancerNonhematologic neoplasmsgynecological cancerendometrial cancer (EC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2031250315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250315.